Cargando…

High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal

BACKGROUND: In Senegal in 2015, an estimated 4800 children were living with HIV, with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized sites outside Dakar. However, until now no studies have determined the efficacy of pediatric treatment in decentralized settings, even...

Descripción completa

Detalles Bibliográficos
Autores principales: Cissé, Abdoul-Magib, Laborde-Balen, Gabrièle, Kébé-Fall, Khady, Dramé, Aboubacry, Diop, Halimatou, Diop, Karim, FatouNiasse-Traoré, Coulibaly, Mohamed, Have, Ndeye-Ngone, Vidal, Nicole, Thiam, Safiatou, Wade, Abdoulaye S., Peeters, Martine, Taverne, Bernard, Msellati, Philippe, Touré-Kane, Coumba
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362577/
https://www.ncbi.nlm.nih.gov/pubmed/30722780
http://dx.doi.org/10.1186/s12887-019-1420-z
_version_ 1783392947721469952
author Cissé, Abdoul-Magib
Laborde-Balen, Gabrièle
Kébé-Fall, Khady
Dramé, Aboubacry
Diop, Halimatou
Diop, Karim
FatouNiasse-Traoré
Coulibaly, Mohamed
Have, Ndeye-Ngone
Vidal, Nicole
Thiam, Safiatou
Wade, Abdoulaye S.
Peeters, Martine
Taverne, Bernard
Msellati, Philippe
Touré-Kane, Coumba
author_facet Cissé, Abdoul-Magib
Laborde-Balen, Gabrièle
Kébé-Fall, Khady
Dramé, Aboubacry
Diop, Halimatou
Diop, Karim
FatouNiasse-Traoré
Coulibaly, Mohamed
Have, Ndeye-Ngone
Vidal, Nicole
Thiam, Safiatou
Wade, Abdoulaye S.
Peeters, Martine
Taverne, Bernard
Msellati, Philippe
Touré-Kane, Coumba
author_sort Cissé, Abdoul-Magib
collection PubMed
description BACKGROUND: In Senegal in 2015, an estimated 4800 children were living with HIV, with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized sites outside Dakar. However, until now no studies have determined the efficacy of pediatric treatment in decentralized settings, even though the emergence of viral resistance, particularly among children in Africa, is a well-known phenomenon. This study aimed to assess the virological status of HIV-infected children in all decentralized facilities to help improve access to quality care. METHODS: A cross-sectional epidemiological and virological study was conducted in all of Senegal’s regions, except Dakar, between March and June 2015 and sought to include all HIV-infected children and adolescents (0–19 years), treated or not with ARVs. Socio-demographic and clinical data and a blood sample on blotting paper were collected for children from treatment sites. Samples were routed on public transportation, assisted by a network of community health workers. A viral load (VL) assay was performed for each child, followed by genotyping when it exceeded 1000 copies/mL (3 log(10)). RESULTS: Of the 851 identified children, 666 (78%) were enrolled in the study. Half of the children were girls, and the average age was 8 years (6 months–19 years). Most of the children (96.7%) were infected with HIV-1, and 90% were treated with ART, primarily with AZT + 3TC + NVP/EFV therapeutic regimen. The median duration of time on ART was 21 months (1–129). VL was measured for 2% of children before this study. Almost two-thirds (64%) of the children are experiencing virological failure. Among them, there was resistance to at least one drug for 86.5% of cases. Also, 25% children presented resistance to one drug and 40% to two out of three. For nearly one-third of the children presenting resistance, none of the three drugs of the treatment was active. Factors associated with virological failure were male sex, follow-up by a generalist rather than a specialist, and treatment interruptions. CONCLUSIONS: We observed a high level of virological failure and a high percentage of viral resistance among children receiving health care in decentralized facilities in Senegal.
format Online
Article
Text
id pubmed-6362577
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63625772019-02-14 High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal Cissé, Abdoul-Magib Laborde-Balen, Gabrièle Kébé-Fall, Khady Dramé, Aboubacry Diop, Halimatou Diop, Karim FatouNiasse-Traoré Coulibaly, Mohamed Have, Ndeye-Ngone Vidal, Nicole Thiam, Safiatou Wade, Abdoulaye S. Peeters, Martine Taverne, Bernard Msellati, Philippe Touré-Kane, Coumba BMC Pediatr Research Article BACKGROUND: In Senegal in 2015, an estimated 4800 children were living with HIV, with 1200 receiving ARV treatment, of whom half had follow-up care in decentralized sites outside Dakar. However, until now no studies have determined the efficacy of pediatric treatment in decentralized settings, even though the emergence of viral resistance, particularly among children in Africa, is a well-known phenomenon. This study aimed to assess the virological status of HIV-infected children in all decentralized facilities to help improve access to quality care. METHODS: A cross-sectional epidemiological and virological study was conducted in all of Senegal’s regions, except Dakar, between March and June 2015 and sought to include all HIV-infected children and adolescents (0–19 years), treated or not with ARVs. Socio-demographic and clinical data and a blood sample on blotting paper were collected for children from treatment sites. Samples were routed on public transportation, assisted by a network of community health workers. A viral load (VL) assay was performed for each child, followed by genotyping when it exceeded 1000 copies/mL (3 log(10)). RESULTS: Of the 851 identified children, 666 (78%) were enrolled in the study. Half of the children were girls, and the average age was 8 years (6 months–19 years). Most of the children (96.7%) were infected with HIV-1, and 90% were treated with ART, primarily with AZT + 3TC + NVP/EFV therapeutic regimen. The median duration of time on ART was 21 months (1–129). VL was measured for 2% of children before this study. Almost two-thirds (64%) of the children are experiencing virological failure. Among them, there was resistance to at least one drug for 86.5% of cases. Also, 25% children presented resistance to one drug and 40% to two out of three. For nearly one-third of the children presenting resistance, none of the three drugs of the treatment was active. Factors associated with virological failure were male sex, follow-up by a generalist rather than a specialist, and treatment interruptions. CONCLUSIONS: We observed a high level of virological failure and a high percentage of viral resistance among children receiving health care in decentralized facilities in Senegal. BioMed Central 2019-02-05 /pmc/articles/PMC6362577/ /pubmed/30722780 http://dx.doi.org/10.1186/s12887-019-1420-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Cissé, Abdoul-Magib
Laborde-Balen, Gabrièle
Kébé-Fall, Khady
Dramé, Aboubacry
Diop, Halimatou
Diop, Karim
FatouNiasse-Traoré
Coulibaly, Mohamed
Have, Ndeye-Ngone
Vidal, Nicole
Thiam, Safiatou
Wade, Abdoulaye S.
Peeters, Martine
Taverne, Bernard
Msellati, Philippe
Touré-Kane, Coumba
High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal
title High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal
title_full High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal
title_fullStr High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal
title_full_unstemmed High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal
title_short High level of treatment failure and drug resistance to first-line antiretroviral therapies among HIV-infected children receiving decentralized care in Senegal
title_sort high level of treatment failure and drug resistance to first-line antiretroviral therapies among hiv-infected children receiving decentralized care in senegal
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362577/
https://www.ncbi.nlm.nih.gov/pubmed/30722780
http://dx.doi.org/10.1186/s12887-019-1420-z
work_keys_str_mv AT cisseabdoulmagib highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT labordebalengabriele highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT kebefallkhady highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT drameaboubacry highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT diophalimatou highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT diopkarim highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT fatouniassetraore highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT coulibalymohamed highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT havendeyengone highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT vidalnicole highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT thiamsafiatou highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT wadeabdoulayes highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT peetersmartine highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT tavernebernard highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT msellatiphilippe highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal
AT tourekanecoumba highleveloftreatmentfailureanddrugresistancetofirstlineantiretroviraltherapiesamonghivinfectedchildrenreceivingdecentralizedcareinsenegal